Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Antipsychotic metabolic effects: Weight gain, diabetes mellitus, and lipidabnormalities
Autore:
McIntyre, RS; McCann, SM; Kennedy, SH;
Indirizzi:
Ctr Addict & Mental Hlth, Mood & Anxiety Disorders Program, Toronto, ON M5T 1R8, Canada Ctr Addict & Mental Hlth Toronto ON Canada M5T 1R8 to, ON M5T 1R8, Canada Univ Toronto, Dept Psychiat, Toronto, ON, Canada Univ Toronto Toronto ON Canada ronto, Dept Psychiat, Toronto, ON, Canada
Titolo Testata:
CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE
fascicolo: 3, volume: 46, anno: 2001,
pagine: 273 - 281
SICI:
0706-7437(200104)46:3<273:AMEWGD>2.0.ZU;2-D
Fonte:
ISI
Lingua:
ENG
Soggetto:
SERUM TRIGLYCERIDE LEVELS; BIPOLAR DISORDER; BODY-WEIGHT; LEPTIN LEVELS; PLASMA-LEVELS; FOOD-INTAKE; CLOZAPINE; OLANZAPINE; SCHIZOPHRENIA; RECEPTORS;
Keywords:
weight gain; obesity; obesity comorbidity; diabetes mellitus; triglyceride; atypical antipsychotics; conventional antipsychotics;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Social & Behavioral Sciences
Clinical Medicine
Citazioni:
111
Recensione:
Indirizzi per estratti:
Indirizzo: McIntyre, RS Ctr Addict & Mental Hlth, Mood & Anxiety Disorders Program, Clarke Site,250 Coll St, Toronto, ON M5T 1R8, Canada Ctr Addict & Mental Hlth Clarke Site,250 Coll St Toronto ON Canada M5T 1R8
Citazione:
R.S. McIntyre et al., "Antipsychotic metabolic effects: Weight gain, diabetes mellitus, and lipidabnormalities", CAN J PSY, 46(3), 2001, pp. 273-281

Abstract

Objective: To review published and nonpublished literature describing changes in weight, glucose homeostasis, and lipid milieu with antipsychotics. Methods: A Medline search was completed using the words weight gain, diabetes mellitus, cholesterol, triglycerides, risperidone, clozapine, olanzapine, quetiapine, ziprasidone, predictors, prolactin, obesity, and conventional antipsychotics. Publications, including original articles, review articles, letters to the editor abstracts or posters presented at professional meetings in the last 4 years, and references from published articles, were collected. Manufacturers, including Eli Lilly Canada Inc, Janssen-Ortho Inc, Pfizer Canada Inc, AstraZeneca Inc, and Novartis Pharmaceuticals, were contacted to retrieve additional medical information. Results: The topic of antipsychotic-induced weight gain is understudied, and there ave relatively few well-controlled studies. Weight gain as a side effect has been described with both conventional and atypical antipsychotics. Moreover, some atypical antipsychotics are associated with de novo diabetes mellitus and increased serum triglyceride levels. Predictors of weight gain may be age, baseline body, mass index, appetite stimulation, previous antipsychotic exposure, and antipsychotic treatment duration. Conclusion: Significant weight gain is reported with the existing atypicalantipsychotics, The weight gain described is highly distressing to patients, may reduce treatment adherence, and may increase the relative risk for diabetes mellitus and hypertriglyceridemia. Physicians employing these agents should routinely monitor weight, fasting blood glucose, and lipid profiles.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 19/01/20 alle ore 00:29:30